Abstract

The traditional treatment of secondary hyperparathyroidism, which affects many patients with chronic kidney disease and is associated with an increased risk of morbidity and mortality, is not very effective. Recent approaches to its management include the use of vitamin D analogues, non-calcium non-aluminium containing phosphate binders, and calcimimetics.

Keywords: Hyperparathyroidism, bone metabolism, chronic kidney disease, end-stage renal disease, vitamin D, calciumsensing receptor, calcimimetics, cinacalcet HCl